Evidence map›Paper›PMID 38959291›Full record

ArticleCancer2024

PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.

Dylan J Martini, Katherine B Case, Derrik Gratz, Kathryn Pellegrini, Elizabeth Beagle, Thomas Schneider, Melad Dababneh, Bassel Nazha, Jacqueline T Brown, Shreyas S Joshi and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Nectin-4-Targeted Radiotheranostics for Personalized Cancer Therapy: A Systematic Review.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Dylan J MartiniDepartment of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
Katherine B CaseEmory University School of Medicine, Atlanta, Georgia, USA.
Derrik GratzDepartment of Bioinformatics, Emory University, Atlanta, Georgia, USA.
Kathryn PellegriniDepartment of Bioinformatics, Emory University, Atlanta, Georgia, USA.
Elizabeth BeagleDepartment of Bioinformatics, Emory University, Atlanta, Georgia, USA.
Thomas SchneiderDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Melad DababnehDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Bassel NazhaDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0001-6385-1329
Jacqueline T BrownDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
Shreyas S JoshiWinship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0002-0020-5298
Vikram M NarayanWinship Cancer Institute of Emory University, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-3731-4209
Kenneth OganWinship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Viraj A MasterWinship Cancer Institute of Emory University, Atlanta, Georgia, USA.
Bradley C CarthonDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
Omer KucukDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.
Lara R HarikDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Mehmet Asim BilenDepartment of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia, USA.ORCID https://orcid.org/0000-0003-4003-1103

Funding

Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
Illumina NovaSeq 6000 High Throughput DNA Sequencer for Emory UniversityS10OD026799 · OD · EMORY UNIVERSITY · PI BOSINGER, STEVEN EDWARD · 2019 to 2019
$985k
NCI NIH HHS P30 CA138292NIH HHS P30CA138292NIH HHS P51 OD011132NIH HHS S10 OD026799
6 · The paper itself

Abstract

backgroundBladder cancer with divergent differentiation (BCDD) comprises a heterogenous group of tumors with a poor prognosis, and differential expression of nectin-4 and programmed death ligand-1 (PD-L1) has been reported in BCDD. Importantly, nectin-4 expression in bladder cancer is associated with response to enfortumab vedotin, and PD-L1 expression is associated with responses to immune checkpoint inhibitors (ICIs).

methodsThe authors conducted a retrospective review identifying 117 patients with advanced or metastatic BCDD who were treated at Winship Cancer Institute from 2011 to 2021. They performed immunohistochemistry staining for nectin-4 and PD-L1 expression by histologic subtype as well as genomic analysis of these patients, including RNA sequencing, whole-exome sequencing, and fusion detection analysis as well as a subgroup genomic analysis of patients with BCDD who received ICIs.

resultsThe results indicated that nectin-4 expression was highest in the groups who had the squamous and plasmacytoid subtypes, whereas the group that had the sarcomatoid subtype (70.8%) had the highest proportion of PD-L1-positive patients. Genomic analysis yielded several key findings, including a 50% RB1 mutation rate in patients who had small cell BCDD, targetable PIK3CA mutations across multiple subtypes of BCDD, and significantly higher expression of TEC in responders to ICIs.

conclusionsIn this study, the authors identified clinically relevant data on nectin-4 and PD-L1 expression in patients with rare bladder tumors. They also identified several novel findings in the genomic analysis that highlight the role of precision medicine in this population of patients. Larger, prospective studies are needed to validate these hypothesis-generating data.

Indexed as

B7-H1 AntigenBiomarkers, TumorCell Adhesion MoleculesUrinary Bladder NeoplasmsAdultAgedAged, 80 and overCell DifferentiationFemaleGenomicsHumansImmune Checkpoint InhibitorsMaleMiddle AgedNectinsRetrospective StudiesB7-H1 AntigenBiomarkers, TumorCD274 protein, humanCell Adhesion MoleculesImmune Checkpoint InhibitorsNECTIN4 protein, humanNectinsantibody–drug conjugatebiomarkers, bladder cancernectin‐4programmed death ligand‐1 (PD‐L1)RNA sequencing (RNAseq)whole‐exome sequencing

Identifiers

PMID38959291
PMCPMC11464191

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.